Are you Dr. Rich?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 27 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4102 N Roxboro St
Durham, NC 27704Phone+1 919-595-2000Fax+1 919-595-2190- Is this information wrong?
Summary
- Dr. Cadmus Rich, MD is an ophthalmologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina.
Education & Training
University of North Carolina HospitalsResidency, Ophthalmology, 1997 - 2000
Carilion Clinic-Virginia Tech Carilion School of MedicineInternship, Transitional Year, 1995 - 1996
University of North Carolina at Chapel Hill School of MedicineClass of 1995
Certifications & Licensure
NC State Medical License 1996 - 2024
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Publications & Presentations
PubMed
- Tumor Pigmentation Does Not Affect Light-Activated Belzupacap Sarotalocan Treatment but Influences Macrophage Polarization in a Murine Melanoma Model.Sen Ma, Ruben V Huis In't Veld, Yang Hao, Zili Gu, Cadmus Rich, Maria Chiara Gelmi, Aat A Mulder, Peter A van Veelen, T Khanh H Vu, Thorbald van Hall, Ferry A Ossendor...> ;Investigative Ophthalmology & Visual Science. 2024 Jan 2
- 1 citationsIn Vitro Testing of the Virus-Like Drug Conjugate Belzupacap Sarotalocan (AU-011) on Uveal Melanoma Suggests BAP1-Related Immunostimulatory Capacity.Sen Ma, Ruben V Huis In't Veld, Alexander Houy, Marc-Henri Stern, Cadmus Rich, Ferry A Ossendorp, Martine J Jager> ;Investigative Ophthalmology & Visual Science. 2023 Jun 1
- 4 citationsImmune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant t...Ruben V Huis In 't Veld, Sen Ma, Rhonda C Kines, Anneli Savinainen, Cadmus Rich, Ferry Ossendorp, Martine J Jager> ;Cancer Immunology, Immunotherapy. 2023 Jul 1
- Join now to see all
Press Mentions
Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual MeetingFebruary 24th, 2020
SUBSPECIALTY NEWS: Gene Therapy Data from AAO, FDA Approval of Beovu, and MoreNovember 1st, 2019- Aura Biosciences Announces Successful Outcome of End of Phase 2 Meeting with FDA ForJanuary 4th, 2019
- Join now to see all
Professional Memberships
- Fellow
